Trial 18M-18-1

PhII-175: Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Bing Xia, M.D.
Other Trial Staff: Victoria Amran, D.M., Gina Tse, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.